Why the FDA Is Paying More Attention to 503A & 503B Pharmacies If you've been watching the compounding space, especially around GLP 1s and peptides, you've probably noticed something. The FDA is paying Why compounding pharmacies matter and why you should care Industry Update: Interim 503A and 503B Bulks Lists New Revisions The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York